This LOD is significantly lower than the typical p-tau231 concentration in CSF of patients with MCI (501 pg/mL) and AD patients (700 pg/mL), showing a strong prospect for early tau protein detection and clinical application. The gene discussed is MAPT; the disease is Alzheimer disease.